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1. INTRODUCTION {#osp4408-sec-0005}
===============

Nearly 14% of the US population has chronic kidney disease (CKD).[1](#osp4408-bib-0001){ref-type="ref"} The presence of CKD is clinically concerning since it increases the risk of cardiovascular disease three‐fold over 5 years compared with people with normal kidney function.[2](#osp4408-bib-0002){ref-type="ref"} Abdominal obesity in particular has been implicated in not only a two‐fold risk of developing CKD but also the associated obesity co‐morbidities hypertension, glucose intolerance, and insulin resistance.[3](#osp4408-bib-0003){ref-type="ref"} Indeed, insulin resistance is tightly associated with inflammation,[4](#osp4408-bib-0004){ref-type="ref"} and there is growing evidence that advanced glycation end products (AGEs), and their receptors are increased during conditions of inflammation.[5](#osp4408-bib-0005){ref-type="ref"} In fact, receptor for AGEs (RAGE) activates cellular signalling pathways, such as nuclear factor‐κB, thereby resulting in disturbances in oxidative stress--mediated vascular dysfunction.[6](#osp4408-bib-0006){ref-type="ref"} As such, RAGE is a novel member of a group of immunoglobins that are implicated in the development of atherosclerosis, metabolic syndrome, and type 2 diabetes.[7](#osp4408-bib-0007){ref-type="ref"}

Interestingly, mice that genetically overexpress RAGE have increased diabetic nephropathy compared with RAGE null mice who do not develop kidney dysfunction.[8](#osp4408-bib-0008){ref-type="ref"} However, the soluble form of RAGE has been suggested to prevent the development and progression of atherosclerosis in diabetic apo‐E‐null mice by acting as a decoy for AGEs.[9](#osp4408-bib-0009){ref-type="ref"} To date, controversy exists surrounding soluble RAGE, with several studies reporting that it is elevated in adults with type 2 diabetes[10](#osp4408-bib-0010){ref-type="ref"}, [11](#osp4408-bib-0011){ref-type="ref"} and impaired renal function[12](#osp4408-bib-0012){ref-type="ref"} but lower in adults with essential hypertension and coronary heart disease.[12](#osp4408-bib-0012){ref-type="ref"}, [13](#osp4408-bib-0013){ref-type="ref"} Therefore, determining the effect of treatments on soluble RAGE is paramount to understanding cardiometabolic risk reduction mechanisms and relevance in people with CKD. Exercise and weight loss interventions reduce cardiometabolic risk by, at least partially, lowering inflammation (eg, fetuin‐A and leptin) related to insulin resistance in adults with obesity.[14](#osp4408-bib-0014){ref-type="ref"}, [15](#osp4408-bib-0015){ref-type="ref"}, [16](#osp4408-bib-0016){ref-type="ref"} As a result, exercise and diet are recommended as a first‐line therapy in weight management and glycemic control. Exercise with weight loss generally improves endothelial function and glucose regulation via reductions in inflammation in adults with CKD,[17](#osp4408-bib-0017){ref-type="ref"}, [18](#osp4408-bib-0018){ref-type="ref"} although not all studies agree.[19](#osp4408-bib-0019){ref-type="ref"} Nevertheless, based on the established health benefits of weight loss, it would seem that soluble RAGE should decrease after interventions aimed at improving insulin sensitivity for glycaemic control in adults with CKD.[17](#osp4408-bib-0017){ref-type="ref"} However, data on the effect of exercise and/or weight loss on soluble RAGE are equivocal, with some showing reductions,[20](#osp4408-bib-0020){ref-type="ref"} increases,[21](#osp4408-bib-0021){ref-type="ref"} or no change.[22](#osp4408-bib-0022){ref-type="ref"}, [23](#osp4408-bib-0023){ref-type="ref"} These studies are limited though to patients with obesity, who have or do not have type 2 diabetes, and there are no data determining the effect of an exercise plus diet intervention programme on soluble RAGE in adults with CKD. To address this gap in the literature, this study tested the hypothesis that lifestyle‐induced weight loss would decrease plasma soluble RAGE in conjunction with improved glucose regulation.

2. METHODS {#osp4408-sec-0006}
==========

2.1. Participants {#osp4408-sec-0007}
-----------------

Eight adults (56.3 ± 2.8 y, BMI: 43.7 ± 2.1 kg/m^2^, Table [1](#osp4408-tbl-0001){ref-type="table"}) with CKD (eGFR: 49.6 ± 3.3 mL/min/1.73 m^2^) volunteered for this study after being identified using electronic medical records. Although some cardiometabolic data were previously reported,[17](#osp4408-bib-0017){ref-type="ref"} the data are provided here for convenience. All participants were nonsmoking, weight stable (\<2 kg in the previous 6 months), sedentary (less than \<60 min/wk), and had blood pressure \< 180/110 mmHg, HbA~1c~ \< 8%, and an eGFR \< 60 mL/min/1.73 m^2^. Participants were verbally briefed about the study and signed written informed consent documents approved by the Cleveland Clinic Institutional Review Board.

###### 

Cardiometabolic risk factors before and after a 12‐week lifestyle intervention

                                                     Pre                Post          *P* Value
  ------------------------------------------ ------------------- ------------------- -----------
  Population (n, M/F)                            8 (2 M, 6F)              ‐               ‐
  Race (W/B)                                         3/5                  ‐               ‐
  Age (y)                                        56.3 ± 2.8               ‐               ‐
  **Body composition**                                                               
  Weight (kg)                                    122.6 ± 7.0         117.3 ± 6.3        .001
  Body mass index (kg/m^2^)                      43.7 ± 2.1          41.8 ± 1.9        \<.001
  Body fat (%)                                   48.5 ± 3.2          46.2 ± 3.1         .001
  Fat‐free mass (kg)                             63.2 ± 3.9          63.4 ± 4.1          .74
  Waist circumference (cm)                       127.3 ± 4.9         123.2 ± 4.7         .02
  **Cardiovascular fitness**                                                         
  Resting heart rate (bpm)                       82.5 ± 1.6          79.0 ± 2.9          .30
  HR max (bpm)                                   155.6 ± 5.8         155.5 ± 6.5         .60
  VO~2~max (L/min)                                2.4 ± 0.2           2.7 ± 0.2        \<.001
  VO~2~max (mL/kg/min)                           20.2 ± 1.6          23.5 ± 1.8        \<.001
  Systolic blood pressure (mmHg)                 137.6 ± 9.1         140.9 ± 7.8         .92
  Diastolic blood pressure (mmHg)                81.6 ± 2.9          82.0 ± 2.6          .94
  **Glucose metabolism**                                                             
  Fasting PG (mg/dL)                             111.2 ± 7.2         91.7 ± 2.0          .03
  Fasting PI (μU/mL)                             36.0 ± 9.2          41.1 ± 16.9         .68
  2‐h PG (mg/dL)                                211.9 ± 31.0         178.7 ± 7.2         .06
  2‐h PI (μU/mL)                                150.2 ± 29.2        110.8 ± 23.3         .07
  Early‐phase PG ~AUC~ (mg/dL^\*^ 30 min)      4275.9 ± 285.7      3635.4 ± 188.9        .10
  Early‐phase PI ~AUC~ (μU/mL^\*^ 30 min)      2366.2 ± 413.2      2382.0 ± 561.1        .97
  Total‐phase PG ~AUC~ (mg/dL^\*^ 120 min)    22 725.9 ± 2313.6   19 077.9 ± 1584.2      .05
  Total‐phase PI ~AUC~ (μU/mL^\*^ 120 min)    14 336.6 ± 2731.2   12 481.8 ± 2513.7      .16
  Insulin sensitivity (au)                        1.9 ± 0.5           2.5 ± 0.5          .02

*Note.* Data reported as mean ± SEM. Insulin sensitivity was estimated via the Matsuda Index.

Abbreviations: AUC = total area under the curve; PG = plasma glucose; PI = plasma insulin; WC = waist circumference.

2.2. Exercise training {#osp4408-sec-0008}
----------------------

Participants were screened with a resting ECG and an incremental maximally graded exercise stress test before participation in the intervention to ensure cardiac function and safety. Participants underwent a supervised progressive treadmill‐walking exercise intervention 5 d/wk for 30 to 60 min/d at approximately 65% to 85% of heart rate max (HR~max~) for 12 weeks. Participants progressed from 30 to 40 min/d during weeks 1 to 4, 40 to 50 min/d during weeks 5 to 8, and 50 to 60 min/d thereafter, all at 85% HR~max~. Exercise was performed in the Exercise Physiology Laboratory located within the CRU, and sessions were supervised by an exercise physiologist and/or nurse. Exercise sessions commenced and ended with an approximate 5‐minute warm‐up and cool‐down on a cycle ergometer. The target exercise intensity was managed using HR monitors (Polar Electro, Inc, Woodbury, New York). Postintervention outcome measures were obtained the following morning approximately 16 to 18 hours after the last exercise session.

2.3. Dietary intervention {#osp4408-sec-0009}
-------------------------

At baseline, resting metabolic rate (RMR) was examined after participants rested in the supine position for 30 minutes following an overnight fast. Expired air (ie, VO~2~ and VCO~2~) was collected using a ventilated hood and indirect calorimetry (Vmax Encore, Viasys, Yorba Linda, California). RMR was multiplied by an activity factor of 1.2 to estimate total daily energy requirements. The registered dietitian developed individualized 500‐kcal hypocaloric diets with 50% to 60% carbohydrate, 25% to 30% fat, and 15% (ie, 0.8‐1.0 g/kg/day) protein for each patient throughout the intervention. Compliance with the diet was monitored weekly by verification of journaling by the participants during visits to the Clinical Research Unit (CRU) for the exercise programme.

2.4. Body composition and aerobic fitness {#osp4408-sec-0010}
-----------------------------------------

After an overnight fast, weight was recorded on a digital platform scale in a hospital gown, and height was measured without shoes using a wall‐mounted stadiometer. Dual X‐ray absorptiometry (DXA; Lunar Prodigy, Madison, Wisconsin) was used to quantify total fat mass, and waist circumference was measured with a plastic tape measure 2 cm above the umbilicus. Maximum oxygen consumption (VO~2~max) was determined using a continuous incremental treadmill exercise test, (Jaeger Oxygcon Pro; Viasys, Yorba Linda, California). The HR~max~ obtained during this test was used during exercise training.

2.5. Cardiometabolic risk {#osp4408-sec-0011}
-------------------------

Resting HR as well as systolic and diastolic blood pressure was recorded in the seated position after approximately 10 minutes of rest. Fasting glucose, insulin, fetuin‐A, and soluble RAGE were obtained from an antecubital vein. A standard 75‐g oral glucose tolerance test (OGTT) was performed to measure postprandial glucose and insulin as previously described.[24](#osp4408-bib-0024){ref-type="ref"} Blood samples were obtained every 30 minutes up to 120 minutes. Total area under the curve (AUC) was calculated using the trapezoidal model. Insulin sensitivity was estimated using the Matsuda Index.[25](#osp4408-bib-0025){ref-type="ref"}

2.6. Biochemical analysis {#osp4408-sec-0012}
-------------------------

Plasma glucose was determined by a glucose oxidase assay (YSI 2300 STAT Plus, Yellow Springs, Ohio). Blood samples were centrifuged at 4°C for 10 minutes at 1000 rpm and then stored at −80°C until subsequent analysis. Plasma soluble RAGE and fetuin‐A were measured using a Human‐specific enzyme‐linked immunosorbent assay (Roche Modular Diagnostics, Indianapolis, Indiana and Quantikine R & D Systems, Minneapolis, Minnesota, respectively). Plasma insulin was measured using a radioimmunoassay (Millipore, Billerica, Massachusetts).

2.7. Statistical analysis {#osp4408-sec-0013}
-------------------------

Pre‐group and post‐group means were compared using the statistical programme R (Mavericks build, R Foundation, Vienna, Austria, 2014). Non‐normally distributed data were log transformed for statistical analysis. All outcomes were assessed using a paired, two‐tailed *t* test. Spearman‐ranked correlation analysis was used to determine associations between variables, and significance was accepted as *P* \< .05. Data are expressed as mean ± standard error of the mean.

3. RESULTS {#osp4408-sec-0014}
==========

3.1. Fitness and body composition {#osp4408-sec-0015}
---------------------------------

Exercise and diet significantly reduced body weight by −4.1 ± 0.6% (*P* \< .001), and this effect was predominately due to a decrease in fat mass (−4.6 ± 0.7%, *P* \< .001) since fat‐free mass was unchanged at the end of the intervention (0.2 ± 1.0%, *P* = .74; Table 1). Exercise training increased VO~2~max (mL/kg/min) by approximately 16.9 ± 2.9% (*P* \< .001).

3.2. Cardiometabolic risk factors {#osp4408-sec-0016}
---------------------------------

The intervention had no significant effect on lowering resting HR or blood pressure (Table [1](#osp4408-tbl-0001){ref-type="table"}). However, exercise plus diet significantly lowered fetuin‐A (pre = 0.92 ± 0.15 vs post = 0.77 ± 0.12 ng/mL, *P* = .02) as well as fasting glucose and improved glucose tolerance as reflected by total phase AUC calculations (Table 1). Exercise training with weight loss increased insulin sensitivity by 29.2 ± 16.0% (*P* \< .02; Table 1).

3.3. Soluble RAGE and correlations {#osp4408-sec-0017}
----------------------------------

Exercise training with weight loss significantly decreased plasma soluble RAGE (pre = 1018.1 ± 163.0 vs post = 810.6 ± 119.6 ng/mL, *P* = .02; Figure [1](#osp4408-fig-0001){ref-type="fig"}). These lower soluble RAGE levels were associated with reductions in 2‐hour blood glucose (*r* = 0.76, *P* = .03, Figure [2](#osp4408-fig-0002){ref-type="fig"}A) and improved insulin sensitivity (*r* = −0.90, *P* \< .01, Figure [2](#osp4408-fig-0002){ref-type="fig"}B). The correlation between changes in body weight (*r* = −0.57, *P* = .15), VO~2~max (*r* = −0.25, *P* = .59), and iGRF (*r* = 0.02, *P* = .97) with reductions in soluble RAGE were not statistically significant.

![Effect of a 12‐week exercise intervention on plasma soluble RAGE concentrations. ^\*^Significant compared with pretest (*P* = .02)](OSP4-6-307-g001){#osp4408-fig-0001}

![Correlation between the change (Δ) in circulating soluble RAGE and glucose tolerance (A) and insulin sensitivity (B) after a 12‐week lifestyle intervention](OSP4-6-307-g002){#osp4408-fig-0002}

4. DISCUSSION {#osp4408-sec-0018}
=============

The main finding from this study is that exercise training plus caloric restriction decreased plasma soluble RAGE concentrations (Figure [1](#osp4408-fig-0001){ref-type="fig"}). The reduction in soluble RAGE was significantly correlated with lower circulating postprandial glucose and increased insulin sensitivity (Figure [2](#osp4408-fig-0002){ref-type="fig"}). These findings are consistent with a recent report that increasing physical activity led to a reduction in soluble RAGE in elderly adults with normoglycemia.[20](#osp4408-bib-0020){ref-type="ref"} In contrast, Danzig et al[23](#osp4408-bib-0023){ref-type="ref"} reported that a single bout of aerobic exercise performed to maximal HR had no effect on soluble RAGE in adults with coronary artery disease. Further adding to the opposing findings, Choi et al[21](#osp4408-bib-0021){ref-type="ref"} demonstrated that 12 weeks of aerobic exercise training raised soluble RAGE in adults with type 2 diabetes, and these findings were directly correlated with reductions in C‐reactive protein. Importantly, unlike previous work,[20](#osp4408-bib-0020){ref-type="ref"}, [21](#osp4408-bib-0021){ref-type="ref"}, [23](#osp4408-bib-0023){ref-type="ref"} the study design herein had participants undergo a rigorous dietary control 3 days before metabolic testing and exercised with full supervision at approximately 65% to 85% of HR~max~ for up to 60 minutes per session 5 d/wk for 12 weeks. Thus, these data strengthen the current body of literature and show for the first time that moderate to vigorous intensity exercise training reduces soluble RAGE in adults with CKD.

The mechanism by which lifestyle‐induced weight loss reduces soluble RAGE has yet to be fully elucidated. Physically active individuals typically have more favourable cardiometabolic profiles than less active people.[26](#osp4408-bib-0026){ref-type="ref"} However, no such correlation of fitness and RAGE was detected in this study, suggesting VO~2~max is unlikely a primary mechanism underlying the reduction in RAGE. Alternatively, renal clearance may be an important factor regulating the removal of AGEs[27](#osp4408-bib-0027){ref-type="ref"} that, in turn, would impact expression of soluble RAGE. Prior work[17](#osp4408-bib-0017){ref-type="ref"} though showed that 12 weeks of lifestyle‐induced weight loss had no effect on kidney function as measured by iGFR, and no such association with soluble RAGE was observed with this same approach in the present study. Thus, changes in soluble RAGE after lifestyle treatment appear independent of renal function. Weight loss on the other hand is established to reduce cardiometabolic disease risk,[28](#osp4408-bib-0028){ref-type="ref"} and some,[20](#osp4408-bib-0020){ref-type="ref"} but not all,[21](#osp4408-bib-0021){ref-type="ref"}, [29](#osp4408-bib-0029){ref-type="ref"} have proposed that decreased body weight per se is directly correlated with reductions in soluble RAGE. While the results presented here are consistent with lifestyle‐induced weight loss altering soluble RAGE in patients with CKD, further work is warranted. Nonetheless, another possible mechanism by which weight loss could have reduced soluble RAGE relates to circulating glucose. Hyperglycaemia induces nonenzymatic alterations in extracellular and intracellular proteins, thereby promoting AGEs and increasing the expression of RAGE.[30](#osp4408-bib-0030){ref-type="ref"}, [31](#osp4408-bib-0031){ref-type="ref"} Although the current study did not measure AGEs, it is worth noting that caloric restriction and 12‐weeks of aerobic exercise decrease AGEs.[32](#osp4408-bib-0032){ref-type="ref"}, [33](#osp4408-bib-0033){ref-type="ref"} Further, a direct correlation between reductions in postprandial plasma glucose and decreased soluble RAGE following lifestyle treatment was observed (Figure [2](#osp4408-fig-0002){ref-type="fig"}A). Thus, reductions in glucose may play a role in affecting the expression of RAGE.

Exercise combined with caloric restriction has been show to improve insulin sensitivity[34](#osp4408-bib-0034){ref-type="ref"} in part through lower inflammation.[15](#osp4408-bib-0015){ref-type="ref"}, [35](#osp4408-bib-0035){ref-type="ref"} Herein, while lifestyle‐induced weight loss was shown to decrease circulating fetuin‐A in patients with CKD, no significant correlation with insulin sensitivity was noted. In contrast, the results of the present study suggest that changes in soluble RAGE after lifestyle‐induced therapy were associated with improvements in insulin sensitivity (Figure [2](#osp4408-fig-0002){ref-type="fig"}B). These findings oppose pharmacological[36](#osp4408-bib-0036){ref-type="ref"} and bariatric surgery interventions[29](#osp4408-bib-0029){ref-type="ref"} that have reported improved insulin sensitivity is related to elevated soluble RAGE. The precise mechanism by which lifestyle‐induced insulin sensitivity associates with decreased soluble RAGE is beyond the scope of the present work, but there are two distinct pathways by which soluble RAGEs are generated. These include (a) the ectodomain shedding of the membrane‐associated receptor and (b) the alternative splicing of RAGE pre‐mRNA transcript.[5](#osp4408-bib-0005){ref-type="ref"} Thus, future work should consider determining the cellular mechanism by which exercise and/or diet affects RAGE in order to optimize therapies for preventing and/or treating diabetic complications.

This study has limitations that may affect interpretation of results. This is a small pilot study, and interpretation should be made with caution. Moreover, despite the absence of an age‐ and weight‐matched control group, recent work demonstrates that soluble RAGE in at‐risk adults for renal dysfunction do not change over a 3‐month period.[21](#osp4408-bib-0021){ref-type="ref"} This provides confidence that the decrease in soluble RAGE observed herein is due to lifestyle‐induced weight loss and not diurnal variation. The intervention selected was a combined exercise plus caloric restriction, thereby limiting ability to isolate exercise versus diet per se. Further work is required to test independent effects of exercise and caloric restriction on soluble RAGE. It is also recognized that this study is specific to patients with stage 2 and 3 CKD, and the data may not be applicable to more or less severe forms of CKD. Further, circulating total soluble RAGE was measured. As a result, results herein may not be generalized or directly compared with studies that have measured endogenous secretory (es)RAGE. This may be of physiologic relevance since esRAGE constitutes only part but not all of the human soluble RAGE in plasma.[37](#osp4408-bib-0037){ref-type="ref"} Nevertheless, these findings have clinical relevance for not only understanding how exercise plus weight loss regulates cytokines implicated in glucose regulation but also providing novel insight that may lay the groundwork for elucidating mechanisms involved in renal rehabilitation.

In conclusion, 12 weeks of aerobic exercise training with weight loss reduced soluble RAGE in previously sedentary, adults with CKD. The decrease in soluble RAGE concentrations was associated with reductions in circulating postprandial blood glucose and elevations in insulin sensitivity. Given that hyperglycaemia is implicated in the development of vascular damage, these findings suggest that soluble RAGE may be an important cytokine related to macrovascular and microvascular complications related to end‐stage organ damage in CKD. Further work is required to elucidate the mechanism whereby different RAGE variants relate to glucose metabolism in order to gain insight into how exercise with weight loss contributes to the prevention and/or reversal of type 2 diabetes and cardiovascular disease in patients with CKD.
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